OncoMatch/Clinical Trials/NCT06859424
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Is NCT06859424 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for aml (acute myelogenous leukemia).
Treatment: Conditioning Regimen A · Conditioning Regimen B · Conditioning Regimen C · Conditioning Regimen D · Conditioning Regimen E · PTCy (50 mg/kg D3, D4) · PTCy (25 mg/kg D3, D4) · Post-transplant Tacrolimus · Post-transplant Mycophenolate mofetil · Post-transplant Abatacept · Post-transplant Ruxolitinib · Supportive Care: Growth Factors · Supportive Care: Seizure prophylaxis · Supportive Care: Prophylaxis against infections — The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who is not related and has a different blood cell type than the study participant. The researchers will compare the new drug combination to a standard drug combination. They will also learn about the safety of each drug combination. Participants will: * Receive the standard or new drug combination after transplant * Visit the doctor's office for check-ups and tests after transplant that are routine for most transplant patients * Take surveys about physical and emotional well-being * Give blood and stool samples.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Chronic Myeloid Leukemia
Chronic Lymphocytic Leukemia
Myeloproliferative Neoplasm
Non-Hodgkin Lymphoma
Demographics
Prior therapy
Cannot have received: allogeneic transplant
Subjects with a prior allogeneic transplant
Cannot have received: autologous transplant
Exception: autologous transplant within the past 3 months
Subjects with an autologous transplant within the past 3 months
Lab requirements
Kidney function
Estimated creatinine clearance ≥ 45mL/min calculated by equation
Liver function
Liver function acceptable per local institutional guidelines
Cardiac function
Left ventricular ejection fraction ≥ 45% (MAC) or ≥ 40% (RIC/NMA) based on most recent echocardiogram or MUGA results
Cardiac function: Left ventricular ejection fraction ≥ 45% (MAC) or ≥ 40% (RIC/NMA); Estimated creatinine clearance ≥ 45mL/min; Liver function acceptable per local institutional guidelines
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama Birmingham · Birmingham, Alabama
- City of Hope · Duarte, California
- Stanford · Palo Alto, California
- University of Miami · Miami, Florida
- University of Kansas Medical Center · Westwood, Kansas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06859424 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic transplant, autologous transplant disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 66 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify